

PAN MERSEY AREA PRESCRIBING COMMITTEE MEETING

**Minutes of the Meeting held on Wednesday 2 November 2016 in
The Community Room, River Alt Resource Centre,
Woolfall Heath Avenue, Huyton. L36 3YE**

Present:

MEMBERS		Present	Apologies
Peter Johnstone (Chair)	Prescribing Commissioner – Liverpool CCG	X	
Dr Sid McNulty (Deputy Chair)	Consultant Endocrinologist/Chair Drug & Therapeutics Committee – St Helens & Knowsley Teaching Hospitals NHS Trust	X	
Catrin Barker	Chief Pharmacist – Alder Hey Children’s NHS Foundation Trust	X	
Dr Rob Barnett	LMC Representative, Liverpool	X	
Adrian Brown	Chief Pharmacist, Southport & Ormskirk NHS Trust	X	
Marie Buckley	Joint Head of Medicines Management – Liverpool Community Health	X	
Dr Ivan Camphor	Mid-Mersey LMC Representative		X
Nicola Cartwright	Acting Deputy Head of Meds Man – St Helens CCG	X	
Neil Chilton	Medicine Management Clinical Services Manager, 5 Boroughs Partnership, Mental Health Trust	X	
Dr John Edwards	GP, St Helens CCG	X	
Dr Anna Ferguson	GP Clinical Lead – South Sefton CCG	X	
Dr Claire Forde	CCG Governing Body Member, Prescribing Lead – Halton CCG	X	
Donna Gillespie-Greene	Head of Medicines Commissioning - Midlands & Lancashire Commissioning Support Unit	X	
Gillian Gow	Chief Pharmacist – Liverpool Heart and Chest FT	X	
Dr Jamie Hampson	GP, Liverpool CCG	X	
Dr Dan Hawcutt	Consultant Paediatrician and Chair of D&T Alder Hey Children’s NHS FT		X
Dr Adit Jain	Clinical Lead, Prescribing – Knowsley CCG	X	
Jenny Johnston	Senior Pharmacist, South Sefton CCG and Southport & Formby CCG	X	
Jenny Jones	Principal Pharmacist Meds Management – Warrington & Halton Hospitals NHS FT	X	
Lee Knowles	Chief Pharmacist – Mersey Care NHS Trust		X
Jenny Lunn	Pharmaceutical Adviser & Team Lead, Medicines Management – Warrington CCG	X	
Susanne Lynch	CCG Lead Medicines Management – South Sefton CCG and Southport & Formby CCG		X
Dr Neil Mercer	Consultant Anaesthetist/Chair Drug & Therapeutics Committee –Aintree University Hospitals NHS Trust	X	
Mark Pilling	Interim Head of Medicines Management – Knowsley CCG	X	
Sarah Quinn	Head of Medicines Management, Bridgewater Community Healthcare NHS Foundation Trust	X	
Lucy Reid	Lead Pharmacist – Halton CCG Locality Medicines Management Team	X	

Paul Skipper	Deputy Director of Pharmacy, The Royal Liverpool & Broadgreen University Hospitals NHS Trust	X	
Dr Octavia Stevens	GP, Southport & Formby CCG	X	
Dave Thornton	Assistant Clinical Director of Pharmacy – University Hospital Aintree	X	
Janet Walsh	Medicines Optimisation Pharmacist – West Lancs	X	
Mike Welsby	Pharmacist – St Helens & Knowsley Teaching Hospitals NHS Trust	X	
IN ATTENDANCE			
Helen Dingle	Senior Prescribing Advisor, MLCSU	X	
Anne Henshaw	Senior Pharmacist – Midlands & Lancs CSU	X	
Joanne McEntee	Senior Medicines Information Pharmacist, North West Medicines Information	X	
Agatha Munyika	Mersey Care NHS Trust		X
Graham Reader	Senior Pharmacist – Midlands & Lancs CSU		X
Claire Sawers	Meds Optimisation Pharmacist, Warrington CCG	X	

1	<p>APC/16/60 – Welcome and Apologies for Absence</p> <p>The Chair welcomed members. In addition, the APC welcomed Dr Adit Jain GP from Knowsley CCG (replacing Dr Hossain); Dr Jain is also Knowsley's GP Education Tutor and works for NHSE as a Medical Adviser. The APC also welcomed Claire Sawers, Medicines Optimisation Pharmacist from Warrington CCG, attending to observe.</p> <p>The Chair accepted apologies from the following: Dr Dan Hawcutt, Vicki Caton (Adrian Brown attending), Agatha Munyika, Lee Knowles, Nicola Baxter (Janet Walsh attending), David Ainscough (Marie Buckley attending), Susanne Lynch (Jenny Johnston attending), Sarah McParland, Dr Ivan Camphor, Alison Ewing/Isam Badhawi (Paul Skipper attending) and Simon Gelder (Mike Welsby attending).</p>	Action:
2	<p>APC/16/61 – Declarations of Interest and Quoracy Check</p> <p>A quoracy check confirmed that this meeting was quorate. There were no declarations of interest.</p>	
3	<p>APC/16/62 – Minutes of the previous meeting and matters arising.</p> <p>16/62/01 – Minutes from the Previous Meeting The Minutes were agreed to be an accurate record of the previous meeting on 28 September 2016.</p> <p>16/62/02 – Matters Arising</p> <p>Declaration of Interest Form At the last meeting a discussion took place about adopting a 'declaration of interest' form. There was a query around how far back the form should cover. DGG looked around at some other APC committees and found that 2 years is the usual period. The APC agreed to 2 years. DGG will bring a form to the next meeting for members to declare anything within the last 2 years, and sign.</p> <p>ADHD Shared Care Update The relevant documents went to the Mid-Mersey LMC meeting on Monday this week for consideration. Feedback from Mid-Mersey LMC has been received just before today's APC meeting, so this will be considered by the Shared Care Subgroup and the APC will be updated with progress at the next meeting.</p> <p>Sodium Oxybate Update A letter was sent to Dr O'Reilly of the Liverpool Sleep Service querying what some of the measures (referred to in his audit report) were. A response has not been received yet. This will be put on next month's agenda.</p> <p>Linezolid At the last APC meeting it was agreed that short-term linezolid up to 10 days duration where the patient is not admitted to hospital is designated as Amber Recommended (where duration >10 days or where patient admitted to hospital designated as Red). It was proposed that the recommendation is changed to: short-term use (up to 14 days) –</p>	<p>DGG</p> <p>HD</p> <p>GR</p>

	<p>Amber recommended AND long-term use (>14 days) and where the patient has been admitted to hospital - Red. DGG confirmed that monitoring is not required until the patient has been taking linezolid for more than 14 days.</p> <p>There were no objections and this amendment was agreed.</p>	
4	<p>APC/16/63 – New Medicines 16/63/01 – Grey Statement Summary <u>Pitolisant film-coated tablets</u>: For narcolepsy, with or without cataplexy. A grey ‘holding’ statement has been uploaded to the Pan Mersey website. The NMSG will review this if a formal application for use is received and prioritised for in-year review.</p> <p>The Committee agreed to the above.</p> <p>16/63/02 – Update to biosimilar insulin statement The Pan Mersey APC approved a green statement for biosimilar insulins in Feb 2016. Since then the FGSG has reviewed and updated Chapter 6 and reclassified all insulins as amber initiated (unless otherwise specified) and this was approved by the APC in September. The RAG rating of the statement has now been brought into line with the new APC approved Amber Initiated status so there is no discrepancy between the statement and the formulary entry. It was proposed to keep the CCG approvals on the formulary if the CCG Leads agreed. There were no objections and the Committee agreed to the proposal.</p> <p>16/63/03 – Secukinumab for ankylosing spondylitis (NICE TA407) NICE TA407 was published at the end of September for the treatment of AS with Secukinumab. Specific criteria for starting and stopping treatment is given. AH gave a summary of the costing information, but noted that costs quoted were before the PAS discount had been applied.</p> <p>A summary of the “Use of biological agents in the management of ankylosing spondylitis and non-radiographic axial spondyloarthritis” statement and the pathway was given.</p> <p>The APC Committee agreed to these 2 statements and the pathway.</p> <p>16/63/04 – Aflibercept for BRVO (NICE TA409) This is based on TA409. Aflibercept can only be used in conjunction with a PAS scheme. The costing information was summarised for members, but noted that costs quoted were before the PAS discount had been applied.</p> <p>There were no comments or questions. The APC Committee agreed to this statement.</p>	
5	<p>APC/16/64 – Formulary and Guidelines 16/64/01 – Formulary Amendments</p> <ul style="list-style-type: none"> • Treclin gel This has not been consulted on, as it is a minor amendment proposed by the Formulary and Guidelines Subgroup. It was proposed to add it to formulary section 13.6.1 as an additional option to Isotrexin gel. A GP suggested that there is a need to extend the formulary for this indication. APC members agreed to this addition. Prescribing data for the product will be brought back when 6 months of data are available. • Carbocisteine sachets It was proposed to add carbocisteine sachets as an additional formulation option to oral liquid and capsules. This offers a slight saving. The APC agreed to this addition to the formulary. <p>16/64/02 – Opioid cross-tapering Comments made during the consultation have all been addressed and wording amended. It was proposed that there should be a Red RAG designation for opioid cross titration. DGG went through the criteria for a red designation.</p> <p>The CSU have asked the CCGs and all are happy to fund the cross titration, with the exception of Halton CCG which has not responded yet. The Halton CCG Lead Pharmacist</p>	GR

	<p>confirmed that this decision is currently with their Finance team.</p> <p>The FGSG proposes that this goes into the formulary as a recommendation. The FGSG were asked to include a definition of 'strong opioid' in the text. It was agreed that this definition can be added without coming back to the APC meeting.</p> <p>The APC agreed to this RAG designation.</p>	
6	<p>APC/16/65 – APC Reports 16/65/01 – NICE TA Adherence Checklist September 2016</p> <p>The September checklist was included on the APC agenda for noting. This item will be on the agenda each month to demonstrate that the APC is getting the TAs through in as timely a manner as possible. There were no questions.</p>	
7	<p>APC/16/66 – Any Other Business 16/66/01 – AOB</p> <p><u>Correspondence from NICE</u>: DGG reminded members that the APC had sent a letter to NICE regarding secubitril/valsartan and a response had been received which the APC felt did not address the issue raised. Another letter was sent to NICE by the APC Chair and their reply has been received this week. In it they state that the recommendation to implement NICE TA 388 within 30 days comes from NHS England and outlined in section 5.1 of the guidance. It was also suggested that the concerns of the Pan Mersey APC should be shared with the NHS England Team.</p> <p>DGG will share the committee's concerns with NHS England as it was felt that the response has not addressed the problem the APC raised.</p> <p><u>APC Meeting Frequency</u>: After a discussion it was decided that the meetings should remain monthly but it was agreed that the APC Chair can cancel meetings if the agenda does not justify a meeting. The decision will be taken 7 days before the next meeting date and before the agenda is sent out.</p>	DGG
8	<p>APC/16/67 Date, Time and Venue of the next meeting</p> <p><u>Date and time of next APC meeting</u>: Wednesday 30 November 2016 at 2.00-4.00pm</p> <p><u>Venue</u>: The Education Centre, Kent Lodge, Broadgreen Hospital, Thomas Drive, Liverpool. L14 3LB.</p>	

The agenda and minutes of this meeting may be made available to public and persons outside of The Pan Mersey Area Prescribing Committee Health Community in order to comply with requests made under the Freedom of Information Act 2000.